Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
May 20th 2011Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?
May 17th 2011Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Are We Winning the War on Cancer?
May 15th 2011With an increasing demand for cancer care driven by the demographics of the aging population far outpacing the supply of oncologists, and the ongoing transformation of the reimbursement system, the challenges facing oncology are formidable.